Drug Trial Radar · NCT05377333
A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Jan 11, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
94
Actual
Start
Jun 2, 2022
Primary completion
Nov 22, 2023
Study completion Nov 22, 2023
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 20 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to investigate the safety and tolerability of the study drug LY3457263 when administered alone or in combination with glucagon-like peptide 1 (GLP-1) receptor agonist (RA) in participants with type 2 diabetes. Blood tests will be performed to investigate how the body processes the study drug and how the study drug affects the body. The study will last up to approximately 16 weeks excluding the screening period for each participant and include up to 17 visits.
Conditions
- Diabetes Mellitus, Type 2
Interventions
LY3457263Drug
Administered SC.
PlaceboDrug
Administered SC.
DulaglutideDrug
Administered SC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationTime frame: Predose up to 16 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Pinnacle Research Group, LLC
Anniston, Alabama
CenExel ACT
Anaheim, California
Qps-Mra, Llc
South Miami, Florida
Atlanta Center of Medical Research
Atlanta, Georgia
CenExel-HRI
Berlin, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.